silo.ai
  • Services
  • Solutions
  • Work
  • Research
  • Contact
  • •••
    • About
    • Careers
    • Learn
Menu
  • Services
  • Solutions
  • Work
  • Research
  • Contact
  • •••
    • About
    • Careers
    • Learn
silo.ai
  • Services
  • Solutions
  • Research
  • About
  • Careers
  • Learn
  • Contact
Menu
  • Services
  • Solutions
  • Research
  • About
  • Careers
  • Learn
  • Contact
Article / News / 
Smart City & Citizens

How Auria Biobank and Silo AI use computer vision to find new information to fight cancer

  • November 9, 2020

Auria Biobank (Turku University Hospital and University of Turku) and Nordic AI service and solution provider Silo AI announce today their collaboration in investigating computer vision-powered solutions for novel cancer diagnostics in digital pathology. The research project focuses on analyzing digital pathology images of tissue samples from one of the most common skin cancers. Silo AI’s AI Scientists leverage computer vision in order to analyze the vast dataset of these digital pathology images. 

Research with the goal of understanding if the cancer will spread

As part of Turku University Hospital, Auria Biobank, is, among other things, a repository of over 1M+ tissue samples from patients. Around 10 similar biobanks in Finland use their samples to contribute to medical research aimed at developing new medications and forms of treatment. In Auria, most of the tissue samples are from different cancers.

Together with Silo AI, Auria set out to investigate whether a certain type of skin cancer will spread to other parts of the body in the future. In scientific terms, it’s about understanding whether the tumor will metastasize or not. The computer vision-based classification is done based on the first digitized tissue sample resected from the patient’s tumor at the time of cancer onset. So far the clinicians have not found reliable markers that would predict later metastasization in the particular cancer under study.

“The skin cancer, cutaneous squamous cell carcinoma, we’re investigating is one of the most common cancers. By leveraging the latest computer vision technologies, our aim is to find significant new information that supports clinicians in their diagnosis work in assessing the risk of metastasis. This is expected to have an important impact on the patient outcome”, says Veli-Matti Kähäri, Professor of Dermatology at Turku University and Chief Physician at The Department of Dermatology of Turku University Hospital.

Kähäri is leading the research group that collaborates with experts from both Silo AI, Auria and Turku University.

The research interest rises from a research paper published in Nature (2018), that investigated lung carcinoma tissue. The paper suggested that determining the tumors’ driving oncogenes might be possible from digitized samples. In a similar vein, the hypothesis is that there might be previously unidentified histopathological differences between those cancer cells that will spread, and those that won’t – and that this could be seen in advance. 

The paper gained significant attention already at the time of publishing, and has been in Auria’s interest ever since, according to Auria’s Director, Lila Kallio:

“We started to investigate the possibilities at Auria for a similar approach immediately as these scientific results were published. For example, we have hundreds of skin cancer samples which can be grouped based on the clinical data collected by the collaborating clinicians at Turku University Hospital, and with the help of Silo AI, we believe we can discover novel significant findings in an efficient way.”

Mikko Tukiainen, AI Scientist at Silo AI, dives deeper into the project: “In short, we’re studying if there exists morphological differences that a computer would be able to see. Human pathologists have so far been unable to identify such features in the cancer in question. For the patients, having the information on whether or not the cancer will become metastatic can be crucial both in terms of on-going treatments but also in understanding the need for follow-up monitoring.”

Explaining AI decision-making helps human pathologists learn from computer vision-based analysis

Understanding the indications of future metastasis will eventually help human pathologists to learn from what the computer vision sees in the cancer tissue. Computer vision permits us to carefully analyze hundreds of images of cancerous tissue, and it is possible that the AI solution is able to find something that humans have so far been unable to see. Therefore, another core element of the project is to be able to explain and show what the AI solution is basing its decisions on. 

For this purpose, Silo AI’s AI Scientists have been creating various decision heatmaps with techniques such as Grad-CAM. With these explanation methods, clinicians are better enabled to unravel what the AI solution sees, as its decision making process may not be intuitive to natural human thinking at first.

By visualizing explanations with Grad-CAM, scientists are able to understand which parts of the image are most affecting the AI decision-making. Here, Grad-CAM highlights the regions that the AI technology judged as tumorous. The image is not related to the Auria project, but is part of a Kaggle challenge that Silo AI’s AI Engineer Joni Juvonen took. Mikko and Joni have taken several Kaggle challenges together to improve cancer tissue analysis with computer vision. 

Vast datasets go all the way down to cellular level

Computer vision-powered analysis is not a trivial task: digital pathology tissue images are extremely detailed as they cover all the way down to the cellular level of the patient. Therefore one single image can be several gigabytes in size, and needs to be treated in smaller pieces.

In addition, the data quality varies because of the different tissue sample staining protocols and scanners used in the different laboratories. Knowing these differences and training the AI model accordingly requires expertise both on the medical and clinical side, and on applying computer vision for human tissue analysis. Mikko, who leads the project at Silo AI, has several years of experience on medical computer vision, and has also published a paper on cancer related research in Finland’s largest medical journal Duodecim.

“I’m passionate about using AI for good. It is extremely interesting to see whether AI technologies can find any indication for a given skin cancer case later becoming metastatic, particularly as currently there are no known clinical, genetical or histopathologic cues for this. Together with Auria, however, I’m confident that we have a good opportunity to leverage both organizations’ expertise and data to find out more.”, Mikko concludes.

The images in this blog post are not related to Auria.


Would you like to take your AI-research to the next level with a partner like Silo AI?

Image of Pertti Hannelin

Get in touch with our VP of Business Development Pertti Hannelin. Pertti is always happy to discuss at pertti.hannelin@silo.ai or to connect on LinkedIn.

Share

Share on twitter
Share on facebook
Share on linkedin

Author

  • Pauliina Alanen Pauliina Alanen

Topics

Computer Vision

You might be interested in

Inference S2 E5: Strategic AI advisory, Errol Koolmeister, The AI Framework

Ville Hulkko 29.6.2022

S2 E5: Errol Koolmeister, CEO of The AI Framework, talks about the role of strategic AI advisory. Errol is one of the most well-known figures in the Nordic AI scene. Known for

Read More

Altor and Silo AI join forces in building a European AI flagship

Mia Jokiluhta 14.6.2022

One of Europe’s largest private AI labs Silo AI announced today that Altor Equity Partners has joined its growth journey as a strategic partner. The partnership and investment allows Silo AI to accelerate its international expansion and further develop its Silo OS infrastructure on its long-term journey to be the European flagship AI company. During the next year, Silo AI plans to establish two new AI hubs in Europe and to hire more than 200 additional AI scientists, with the objective to help more companies build safe, human-centric AI.

Read more

Read More

We challenge you to ask why

We don’t only deliver projects but we challenge you to think different.
Contact

Subscribe to Silo AI newsletter

Join 3000+ subscribers who read the Silo AI monthly newsletter

silo.ai
Contact

+358 40 359 1299

info@silo.ai

  • Helsinki, Finland
  • Stockholm, Sweden
  • Copenhagen, Denmark
Menu
  • Home
  • Services
  • Solutions
  • Research
  • Work
  • About
  • Careers
  • Contact
Menu
  • Home
  • Services
  • Solutions
  • Research
  • Work
  • About
  • Careers
  • Contact
Resources
  • Learn
  • Inference podcast
  • For media
  • MLOps
  • Predictive maintenance
  • Nordic State of AI report
Menu
  • Learn
  • Inference podcast
  • For media
  • MLOps
  • Predictive maintenance
  • Nordic State of AI report
Linkedin Facebook-square Twitter Instagram Spotify
©2017-2022 All Rights Reserved.

|

Website Privacy Policy / Cookie Policy / Newsletter Privacy Policy / Recruitment Privacy Policy

Manage cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Read Cookie Policy
Cookie SettingsAccept All
Manage cookies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
Powered by CookieYes Logo